Regeneron Loses Bid To Be Held Immune From Allegations That It Misused Patented Protein While Testing COVID-19 Treatment

Reuters (10/4, Brittain) reported, “Regeneron Pharmaceuticals lost a bid on Friday to be held immune from allegations that it misused a patented protein while testing a COVID-19 treatment.” According to Reuters, “U.S. District Judge Philip Halpern rejected Regeneron’s pretrial argument that he should throw out Allele Biotechnology and Pharmaceuticals’ patent lawsuit over the treatment based on a federal law allowing the use of patented inventions to test drugs during the U.S. Food and Drug Administration application process.” Allele Biotechnology and Pharmaceuticals “sued Regeneron in 2021, accusing the rival biotech company of using Allele’s fluorescent protein mNeonGreen to test its coronavirus antibody cocktail REGEN-COV [casirivimab/imdevimab] without a license.”